Form 4: C4 Therapeutics CEO Andrew Hirsch Reports Stock Transactions

Andrew Hirsch, CEO of C4 Therapeutics, reports acquisition of restricted stock units and stock options, as well as shares withheld for tax obligations.

Summary

• Andrew Hirsch, the President & CEO of C4 Therapeutics, reported transactions involving the company's common stock and derivative securities.
• On February 14, 2025, Hirsch acquired 223,500 shares of common stock through restricted stock units (RSUs) at a price of $0.
• On the same day, 12,847 shares were withheld by the issuer to cover tax obligations related to the vesting of RSUs at $3.18 per share.
• On February 15, 2025, an additional 9,370 shares were withheld for tax obligations at $3.18 per share.
• Hirsch also acquired options to buy 335,300 shares of common stock at an exercise price of $3.18, which vest monthly starting March 14, 2025, and expire on February 13, 2035.
• Following these transactions, Hirsch directly owns 423,145 shares of common stock and options for 335,300 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects standard insider trading activity. The acquisition of RSUs and options is a positive sign, but the tax withholding is a neutral event.

Positives

• The acquisition of restricted stock units and stock options by the CEO demonstrates confidence in the company's future performance.

Negatives

• Shares were withheld to cover tax obligations, which reduces the CEO's directly held shares.

Industry Context

Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding executive compensation and ownership.

Key Dates

Keywords

C4 Therapeutics, Andrew Hirsch, stock options, restricted stock units, Form 4, beneficial ownership, tax withholding, CCCC